Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial

Bibliographic Details
Title:	Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial
Authors:	Jorda, Anselm ^a, Prager, Marlene ^a, Pracher, Lena ^a, Haselwanter, Patrick ^{a, b}, Jackwerth, Matthias ^a, al Jalali, Valentin ^a, Yildiz, Erdem ^{a, c}, Leutzendorff, Amelie ^{a, d}, Weber, Maria ^a, Yourieva, Schermin ^a, Kammerer, Paula ^a, Pecho, Theresa ^a, Decaminada, Alice ^a, Ederer, Lena ^e, Wiedermann, Ursula ^e, Weseslindtner, Lukas ^f, Redlberger-Fritz, Monika ^f, Bergmann, Felix ^a, Zeitlinger, Markus ^{a, ⁎}
Source:	In Journal of Infection February 2025 90(2)
Database:	ScienceDirect